文献速递泌尿男性生殖肿瘤

血浆微精蛋白β在前列腺癌中的作用:欧洲癌症与营养前瞻性调查中的观察性巢式病例对照与孟德尔随机化研究

The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition.
PubMed 文献 · Ann Oncol · 2019-01-01

在EPIC队列1871例前列腺癌病例与1871例匹配对照中,校正总前列腺特异性抗原后,血浆MSP最高四分位组较低四分位组前列腺癌风险降低(OR=0.65,95%CI 0.51-0.84,P趋势=0.001)。孟德尔随机化分析支持MSP对前列腺癌风险可能具有因果保护作用(每增加1 ng/ml的OR=0.96,95%CI 0.95-0.97)。

要点

  • 校正总PSA后,血浆MSP最高 vs 最低四分位前列腺癌风险OR=0.65(95%CI 0.51-0.84)。
  • rs10993994 TT较CC纯合子血浆MSP低66%(每等位基因差值6.09 ng/ml,95%CI 5.56-6.61)。
  • 孟德尔随机化分析支持MSP对前列腺癌风险可能具有因果保护作用(每1 ng/ml OR=0.96,95%CI 0.95-0.97)。

核心结论

  • 在这项大型欧洲前瞻性研究中,循环MSP浓度高的男性前列腺癌风险较低。
  • MSP可能在前列腺癌中发挥因果保护作用。

研究设计与样本

  • 在欧洲癌症与营养前瞻性调查(EPIC)中开展巢式病例对照研究,纳入1871例病例和1871例匹配对照。
  • 采用条件logistic回归分析诊断前循环MSP与总体及按肿瘤亚型发生前列腺癌风险的关联。
  • 将EPIC估计值与已发表数据合并,采用两样本逆方差法计算孟德尔随机化估计。

主要发现

  • 校正总前列腺特异性抗原浓度后,血浆MSP浓度与前列腺癌风险呈负相关(MSP最高 vs 最低四分位OR=0.65,95%CI 0.51-0.84,P趋势=0.001)。
  • 该关联按肿瘤分期或组织学分级未见异质性。
  • rs10993994 TT纯合子较CC纯合子血浆MSP浓度低66%(每等位基因MSP差值6.09 ng/ml,95%CI 5.56-6.61,r2=0.42)。
  • 孟德尔随机化分析支持MSP与前列腺癌风险可能存在因果保护关联(每1 ng/ml MSP增加MR的OR=0.96,95%CI 0.95-0.97 vs EPIC观察性OR=0.98,95%CI 0.97-0.99)。

局限性

  • 缺乏完整的肿瘤亚型信息。
  • 对MSP生物学功能的信息更完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microseminoprotein-beta (MSP), a protein secreted by the prostate epithelium, may have a protective role in the development of prostate cancer. The only previous prospective study found a 2% reduced prostate cancer risk per unit increase in MSP. This work investigates the association of MSP with prostate cancer risk using observational and Mendelian randomization (MR) methods. PATIENTS AND METHODS: A nested case-control study was conducted with the European Prospective Investigation into Cancer and Nutrition (EPIC) with 1871 cases and 1871 matched controls. Conditional logistic regression analysis was used to investigate the association of pre-diagnostic circulating MSP with risk of incident prostate cancer overall and by tumour subtype. EPIC-derived estimates were combined with published data to calculate an MR estimate using two-sample inverse-variance method. RESULTS: Plasma MSP concentrations were inversely associated with prostate cancer risk after adjusting for total prostate-specific antigen concentration [odds ratio (OR) highest versus lowest fourth of MSP = 0.65, 95% confidence interval (CI) 0.51-0.84, Ptrend = 0.001]. No heterogeneity in this association was observed by tumour stage or histological grade. Plasma MSP concentrations were 66% lower in rs10993994 TT compared with CC homozygotes (per allele difference in MSP: 6.09 ng/ml, 95% CI 5.56-6.61, r2=0.42). MR analyses supported a potentially causal protective association of MSP with prostate cancer risk (OR per 1 ng/ml increase in MSP for MR: 0.96, 95% CI 0.95-0.97 versus EPIC observational: 0.98, 95% CI 0.97-0.99). Limitations include lack of complete tumour subtype information and more complete information on the biological function of MSP. CONCLUSIONS: In this large prospective European study and using MR analyses, men with high circulating MSP concentration have a lower risk of prostate cancer. MSP may play a causally protective role in prostate cancer.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Smith Byrne K, Appleby PN, Key TJ, et al. The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition. Ann Oncol. 2019. PMID: 31089709. doi:10.1093/annonc/mdz121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。